Clinical Trial Search

Primary: Percent Change From Randomization in Body Weight at Week 88 — 14.8; -6.7 percent change — p=<.001

Primary: Minimum Stent Area After Percutaneous Coronary Intervention — 6.7; 6.9 mm^2

Primary: Viral-capsid Protein 1 (VP1)-Specific Antibody Secreting Cells (ASC) by Enzyme-linked Immunospot (ELISpot) Assay — 1.3; 0.5; 0.3; 127.6 Spot Forming Units per 10^6 PBMC

Primary: Relapse Rate — 20; 2; 10 Participants

Primary: Difference in Learning Rate — 0.009; 0.0058 unitless

Primary: Mean Change in the Ability to Implement COVID-19 Health Guidelines Among African American Churches in South Los Angeles 3 Months After Workshop — 3.00000 score on a…

Primary: Change in Internal Dose of Urinary Phthalate Metabolites — 1.9 percent change of sumLMW

Primary: Change From Baseline in Calorie Intake in Participants Receiving Tirzepatide or Placebo at Week 3 — 10.95; -523.15 kilocalories (kcal) — p=<.0001

Primary: Accuracy and Precision of a Mobile Health Application (Cap App) — 0.01 seconds

Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) — -316.60; -127.41 mL/Year

Primary: Objective Response Rate Per Composite Response Criteria — 7.5; 48.6; 33.3 percent of participants

Primary: Lower Extremity Motor Activity Log - Real World Use of the Affected Lower Extremity in Daily Activities. — 6.3; 6.4; 7.3; 7.2 score on a scale

Primary: Onset of Lactogenesis Stage II Through Volume Attainment — 84.8; 81 hours — p=0.985

Primary: Incidence of Clinical Malaria Meeting the Primary Case Definition — 0.45; 0.36 events per person-year — p=0.154

Primary: Attrition Rate — 2 Participants